Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2022.01.21.22269322: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The ethics committee of Shiraz University of Medical Sciences (IR.SUMS.MED.REC.1399.550) approved the study. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources SAS Institute Inc. SAS Institutesuggested: (Statistical Analysis System, RRID:SCR_008567)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There are a couple of limitations in the current …
SciScore for 10.1101/2022.01.21.22269322: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The ethics committee of Shiraz University of Medical Sciences (IR.SUMS.MED.REC.1399.550) approved the study. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources SAS Institute Inc. SAS Institutesuggested: (Statistical Analysis System, RRID:SCR_008567)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There are a couple of limitations in the current study, including not having a double-blind design, and statistically significant difference in clinical score between two groups at initial presentation. However, given the range of 0-29, the difference of 2 points in the severity score may not be as critical because both groups average above 4 and hence are deemed comparable in terms of adverse outcome potential (35). Furthermore, almost half of the patients (57.3% control, and 49.5% combination) had COVID-19 positive PCR results, and others had history of exposure to COVID-19 with typical manifestations. We assumed that recall bias and loss to follow-up are distributed evenly across the two cohort groups. In conclusion, combination of sitagliptin and spironolactone can reduce hospitalization, ER visits and duration of disease in acutely ill outpatient COVID-19 cases significantly. However, running a double blind, randomized, placebo-controlled trial is required to further substantiate the beneficial effects of this combination therapy in COVID-19 patients.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-